Canada’s Vaccine Industry Committee

Vaccine Industry Collaborating To Develop Solutions For COVID-19

Canada’s Vaccine Industry Committee (VIC) collectively recognizes the responsibility that we have in working closely with the Government of Canada to safeguard public health and mitigate the impact of COVID-19. The (VIC) is currently engaged with Health Canada and Public Health Agency of Canada to mobilize the full scope of our scientific and manufacturing resources to respond to the current crisis. Our focus is to maintain the current supply of vaccines for all vaccine preventable diseases in Canada. Vaccine Industry Committee members will continue to proudly play their part, and work closely with all levels of government, the research community and public agencies to develop solutions to address our current and future Canadian vaccine supply needs. As an industry, we are committed to dedicating and sharing our scientific expertise, technical skills and manufacturing capabilities to address this unprecedented global health crisis. We are proud to share current examples of our collaborative industry leadership.


AstraZeneca recently announced a landmark agreement to collaborate with the University of Oxford on the development and distribution of the University’s potential recombinant adenovirus vaccine (AZD1222) aimed at preventing COVID-19 infection. Additionally, through the company’s scientific expertise in infectious disease and proprietary antibody discovery technology, AstraZeneca has been working to identify monoclonal antibod¬ies that have the potential to recognize, bind to and neutralize the SARS-CoV-2 virus.


A CDMO offering process and analytical development as well as both GMP and non-GMP production services for various biologic products, including vaccines and adjuvants. Biodextris is currently involved in the development of a number of vaccines and therapeutics including those to treat and stop the spread of COVID19.


Since the pandemic began, GSK has been seeking ways to harness its scientific expertise and technology to make a difference and is working with scientific partners to develop a broad portfolio of potential COVID-19 solutions covering prevention to treatment. Locally, GSK’s Ste. Foy, Quebec influenza manufacturing site will play a role in GSK’s COVID-19 response, specifically the filling of adjuvant into vials and packaging.

Across all of our COVID-19 solutions GSK is committed to: working in partnership; taking a global approach; ensuring a commitment to access; and supporting future pandemic preparedness. Learn more about GSK’s COVID-19 solutions.


IMV Inc. is developing a vaccine against the SARS-CoV2 based on its unique DPX platform that activates B and T cells responses, even in older or immunocompromised adults. Fully synthetic, DPX COVID-19 offers the potential for accelerated development and rapid, large-scale production. First patient should receive DPX-COVID-19 during summer 2020. Learn more.


During these challenging times we continue to be guided by Our Credo, the values that challenge us to put the needs and well-being of the people we service first. That’s why as a global health leader, our top priority remains our patients, customers and employees.

Johnson & Johnson announced on March 5, 2021 that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. Learn more.


Medicago, a biopharmaceutical company headquartered in Quebec City, currently conducting the Phase 3 portion of its Phase 2/3 clinical study for its plant-derived COVID-19 vaccine candidate. The company successfully produced a Virus-Like-Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene back in March 2020. Since then, Medicago has completed Phase 1 and Phase 2 portions of the clinical development of its vaccine candidate and is expecting the study to be completed by the end of spring 2021. Learn more.


Merck makes a range of medicines and vaccines for infectious diseases. We are actively engaged in scientific efforts to develop safe and effective therapeutics against COVID-19. We are also mobilizing our research partners and networks across Canada to help support COVID-19 related research efforts.


Pfizer has outlined a five-point plan calling on the biopharmaceutical industry to collaborate to combat COVID-19. The plan is intended to help scientists bring forward therapies and vaccines to help protect humankind from the pandemic and prepare the industry to respond to future global health crises.

On December 9, 2020, Pfizer Canada and BioNTech announced that Health Canada granted Authorization under Interim Order for the emergency use of their COVID-19 vaccine. The first doses of the vaccine were administered in Canada on December 14, 2020. On September 16, 2021, Health Canada granted full approval (Notice of Compliance or NOC) for the vaccine to prevent COVID-19 in individuals 12 years of age and older. It is now commercialized under the brand name COMIRNATY ®.

Additionally, Pfizer is actively involved in the research of potential antiviral therapies.


Will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with BARDA. More information can be found here.


Valneva, a specialty vaccine company focused on prevention against infectious diseases with major unmet medical needs, and Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, are collaborating to develop a highly purified inactivated vaccine candidate against the novel SARS-COV-2 coronavirus. Learn more.


VBI and the National Research Council of Canada (NRC) announced a collaborative research agreement to develop a broadly protective pan-coronavirus vaccine candidate including COVID-19. The vaccine builds on the safe and potent clinical history of VBI’s enveloped Virus Like Particle (eVLP) platform. Learn more.


Virica would like to collaborate with developers of virus-based vaccines who are looking to increase manufacturing yields. Virica will provide evaluation quantities of our VSe compounds under a material transfer agreement in order to facilitate the testing and use of our technology in vaccine production. We will work closely with partners to develop VSe formulations for their unique manufacturing processes and support regulatory submissions, where necessary. Learn more. 


Their scientists were the first in Canada to isolate the COVID-19 virus, in collaboration with PHAC and Sunnybrook and are developing a candidate vaccine for COVID-19. Recent vaccine results demonstrated the vaccine induced a strong immune response, generated neutralizing antibodies, and decreased virus in the upper respiratory tract to almost undetectable levels. VIDO-InterVac is excited by these results and are continuing to develop our vaccine towards regulatory approval.

Access by external groups to VIDO-InterVac’s containment level 3 facility is available through contract requests. Learn more.

Want to learn more about vaccine development and manufacturing in Canada? Click here for presentation.

For more information on vaccines in Canada, please see White paper series here.

Leadership In Global Health

Vaccine Industry Committee members are the leading vaccine manufacturers serving the Canadian market and early stage Canadian companies developing advanced vaccine technologies.

The Committee works to shape public policy to:

  • Ensure a secure supply of vaccines for Canada;
  • Advocate for equitable access to vaccines for all Canadians;
  • Promote the value of immunization as one of the most cost-effective health interventions available;
  • Increase uptake for recommended vaccines; and
  • Expand Canadian vaccine innovation and manufacturing capacity

Position Statement 
BIOTECanada’s Vaccine Industry Committee works to ensure a secure supply of vaccines for Canada, advocates for equitable access to vaccines for all Canadians, and promotes the value of immunization as one of the most cost-effective health interventions available.

  • The committee supports the WHO’s position of vaccines hesitancy being one of the top public health threats.
  • Vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – threatens to reverse progress made in tackling vaccine-preventable diseases.
  • Vaccination is one of the most cost-effective ways of avoiding disease – it currently prevents 4-5 million deaths a year worldwide. (Reference)
  • The committee is working with our partner members on ensuring that Canadians have access to balanced information about the broad public health benefits of vaccination.

Want to learn more about vaccine development and manufacturing in Canada? Click here for presentation.

For more information about BIOTECanada’s Vaccine Industry Committee, contact Ron Boch.

Vaccine Industry Committee Members